Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Steg, P. G.
Right arrow Articles by Tchetche, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Steg, P. G.
Right arrow Articles by Tchetche, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Pharmacologic management of stable angina: role of ivabradine

Philippe Gabriel Steg* and Didier Tchetche

Cardiology, Centre Hospitalier Bichat-Claude Bernard, 46 rue Henri Huchard. 75018 Paris, France

* Corresponding author. Tel: +33 1 40 25 86 68; fax: +33 1 40 25 88 65. E-mail address: gabriel.steg{at}bch.aphp.fr

The current management of patients with stable angina involves control of symptoms, prevention of major cardiovascular events, and treatment of risk factors. Usually, this requires the prescription of multiple pharmacological agents. Recent registries have shown that, despite the use of polypharmacy, many patients have poor symptom control, poor compliance with therapy, suboptimal dosages of drugs, or side effects from medications. In addition, the choice of anti-anginals is often limited in patients with comorbidities, such as heart failure or asthma. Overall, persistent symptoms and/or side effects from treatments affect the quality of life of angina patients. Ivabradine is a specific inhibitor of the If current that lowers heart rate without impacting contractility, conduction, or repolarization. It is safe and its most frequent side effects are mild, dose-related, transient, and reversible visual symptoms. Its clinical efficacy has been established by a series of randomized trials, which have, in particular, outlined that ivabradine is non-inferior to atenolol or amlodipine, has prolonged efficacy over 1 year and is well tolerated. This promising agent has a role in the management of patients with stable angina, particularly when beta-blockers are contraindicated or poorly tolerated, and in addition to other anti-anginals when control of symptoms is insufficient.

Key Words: Beta-blockers • Heart rate • Ischaemia • Ivabradine • Stable angina


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.